RE: RE: RE: RE: RE: RE: RE: BoDThe fact that you would try so hard to twist what I have said to make it all negative is impressive. You have your view, I have mine, we are both looking at the same glass... I just see it as half full you see it as half empty. I look at the available information and think that the stock is worth buying... you don't. I think they have a good shot in the fall... you don't.
I guess we will have to agree to disagree.
PS. Phase III can have between 300- 3000+ subjects... my point was that the FDA may require the higher end of that spectrum... sorry if I referenced the wrong site by accident.